Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.
|Articles|April 1, 2013
- April 2013
- Volume 29
- Issue 2
CME Test
Advertisement
Articles in this issue
over 13 years ago
What Your Patients Are Readingover 13 years ago
The YOGA My Heart Studyover 13 years ago
Diuretic Use in Black Patients With Uncontrolled HypertensionAdvertisement
Related to this article
The FDA set a June 18, 2027, PDUFA date for the subcutaneous GP IIb/IIIa inhibitor, based on phase 3 CeleBrate data.
Stay up-to-date with the latest FDA approvals, trial readouts, and key clinician insights across cardiovascular care.
FDA novel drug approvals in Q3 2026: 22 new therapies, including enlicitide, daraxonrasib, oveporexton, and first treatments for rare diseases.
FDA approved mavacamten for oHCM in children weighing 30 kg or more after SCOUT-HCM showed a 48.0-mm Hg Valsalva LVOT gradient reduction vs placebo.
Jesus Almendral, MD, and Kanika Mody, MD, join the HCPLive team to discuss increases in hypertensive heart disease, heart failure, and other conditions.
Preview the biggest anticipated FDA decisions of Q4 2026, including bepirovirsen for CHB, obinutuzumab for pMN, bezuclastinib for systemic mastocytosis, and more.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
FDA Updates Sotatercept Label, ERS Releases PAH Guidelines Based on HYPERION Data
5